Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosravuconazole phase 3 study for eumycetoma requiring surgery
PACTR202607548647895Phase 3Not yet recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of fosravuconazole in eumycetoma, sponsored by Drugs for Neglected Diseases initiative. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
fosravuconazole
03
Conditions
eumycetoma
Beyond the preview
Go deeper on PACTR202607548647895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607548647895.